Phase III Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study

• Status: Recruiting
• Trial end date: 2024-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The Phase III main study is a randomized, controlled, multicenter, double-masked, parallel trial to evaluate the efficacy and safety of 0.25% TP-03, for the treatment of Demodex blepharitis in China. The PK sub-study is a single-arm, open-label trial to evaluate systemic Lotilaner PK of 0.25% TP-03 in whole blood following topical ocular administration

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LianBio LLC

Criteria

Inclusion Criteria:

1. Male or female, aged ≥ 18 years of age.

2. Be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol.

3. Has blepharitis

4. Stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria:

1. Have used lid hygiene products (e.g., lid scrubs) within 14 days of Screening or unwilling to forego the use of lid hygiene products during the study.

2. Have initiated treatment with an ocular topical prostaglandin analogue within 30 days of Screening or have any plans to change or discontinue treatment during the study

3. Pregnancy or lactation.

4. Any intraocular surgery (including ocular surface surgery, cataract surgery and intravitreal injection) or periocular surgery within 60 days prior to randomization, or any planned ocular surgical procedure during the study period

5. Have any unstable or uncontrolled, cardiac, pulmonary, renal, oncological, neurological, metabolic or other systemic condition that, in the opinion of the investigator, would possibly require the participant to seek emergent medical treatment during the course of this study. This includes, but is not limited to, unstable or uncontrolled cardiac arrhythmias, hypertension, coagulopathies, renal failure or advanced diabetes mellitus.